A Treat to Target Approach Decreases the Rate of CD‐Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM2017 ACG Governors Award for Excellence in Clinical Research: 598. (October 2017)